Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease
Although mRNA-based vaccines against SARS-CoV-2 induce a robust immune response and prevent infections and hospitalizations, there are limited data on the antibody response in individuals with humoral immunodeficiency. The aim of this study was to evaluate the humoral immune response after two vacci...
Gespeichert in:
| Veröffentlicht in: | PloS one 2022-06, Vol.17 (6), p.e0268780-e0268780 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0268780 |
|---|---|
| container_issue | 6 |
| container_start_page | e0268780 |
| container_title | PloS one |
| container_volume | 17 |
| creator | Bitzenhofer, Michaela Suter-Riniker, Franziska Moor, Matthias B Sidler, Daniel Horn, Michael P Gschwend, Anna Staehelin, Cornelia Rauch, Andri Helbling, Arthur Jörg, Lukas |
| description | Although mRNA-based vaccines against SARS-CoV-2 induce a robust immune response and prevent infections and hospitalizations, there are limited data on the antibody response in individuals with humoral immunodeficiency. The aim of this study was to evaluate the humoral immune response after two vaccine doses with BNT162b2 or mRNA-1273 in patients with humoral immunodeficiency disease.
This cross-sectional study assessed 39 individuals with hypogammaglobulinemia under immunoglobulin replacement therapy. IgG anti-SARS-CoV-2 spike protein antibodies (anti-S) were measured 4 weeks to 4 months after two doses of an mRNA vaccine against SARS-CoV-2. The proportion of patients, who developed a humoral immune response to the spike protein were evaluated and compared to 19 healthy controls.
After vaccination with two vaccine doses, 26/39 patients (66.7%) with humoral immunodeficiency disease and all healthy controls developed anti-S. In subjects with baseline IgG |
| doi_str_mv | 10.1371/journal.pone.0268780 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2686269663</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A706532793</galeid><doaj_id>oai_doaj_org_article_b2a5f262276d4a26a74b0d1b03d465c0</doaj_id><sourcerecordid>A706532793</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-2e8dfca4907f57b2c4a5f4ccc1ee208e461221cc65dc74392c1c71df65e65c353</originalsourceid><addsrcrecordid>eNqNk11v0zAUhiMEYh_wDxBYQkJwkeKv2MkNUlUBqzQxqYXdWq5z0rpK4i52xvbvcWk2NWgXyBe27Oe8x359TpK8IXhCmCSft67vWl1Pdq6FCaYilzl-lpySgtFUUMyeH61PkjPvtxhnLBfiZXLCMiELyuhpUl30jet0jTrwUckDCg41ix9TdKuNsS14pNfatj6g5XSxTGfuOqXItming4U2ePTbhg3aDCq2afrWlVBZE0_NPSqtB-3hVfKi0rWH18N8nvz69vXn7CK9vPo-n00vUyMKGlIKeVkZzQssq0yuqOE6q7gxhgBQnAMXhFJijMhKIzkrqCFGkrISGYjMsIydJ-8OurvaeTVY5FV0R1BRCMEiMT8QpdNbtetso7t75bRVfzdct1a6C9bUoFY0ZqeCUilKrqnQkq9wSVaYlTymw1Hry5CtXzVQmuhHNGEkOj5p7Uat3a0qSE4zQaPAx0Ggczc9-KAa6w3UtW7B9ft7Sy4zxkUR0ff_oE-_bqDWOj7AtpWLec1eVE0lFhmjsthTkyeoOEporIn1VNm4Pwr4NAqITIC7sNa992q-XPw_e3U9Zj8csRvQddh4V_fBxlIcg_wAms5530H1aDLBat8OD26ofTuooR1i2NvjD3oMeqh_9gfVugTf</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2686269663</pqid></control><display><type>article</type><title>Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Bitzenhofer, Michaela ; Suter-Riniker, Franziska ; Moor, Matthias B ; Sidler, Daniel ; Horn, Michael P ; Gschwend, Anna ; Staehelin, Cornelia ; Rauch, Andri ; Helbling, Arthur ; Jörg, Lukas</creator><creatorcontrib>Bitzenhofer, Michaela ; Suter-Riniker, Franziska ; Moor, Matthias B ; Sidler, Daniel ; Horn, Michael P ; Gschwend, Anna ; Staehelin, Cornelia ; Rauch, Andri ; Helbling, Arthur ; Jörg, Lukas</creatorcontrib><description>Although mRNA-based vaccines against SARS-CoV-2 induce a robust immune response and prevent infections and hospitalizations, there are limited data on the antibody response in individuals with humoral immunodeficiency. The aim of this study was to evaluate the humoral immune response after two vaccine doses with BNT162b2 or mRNA-1273 in patients with humoral immunodeficiency disease.
This cross-sectional study assessed 39 individuals with hypogammaglobulinemia under immunoglobulin replacement therapy. IgG anti-SARS-CoV-2 spike protein antibodies (anti-S) were measured 4 weeks to 4 months after two doses of an mRNA vaccine against SARS-CoV-2. The proportion of patients, who developed a humoral immune response to the spike protein were evaluated and compared to 19 healthy controls.
After vaccination with two vaccine doses, 26/39 patients (66.7%) with humoral immunodeficiency disease and all healthy controls developed anti-S. In subjects with baseline IgG <3 g/l, only 1/5 (20%) showed a humoral immune response. 10 out of 26 with CVID (38.5%) and 7/9 under immunosuppressive drugs (77.8%) developed no immune response (13 subjects with no response) compared to 0/19 in healthy controls. Subgroup analysis in patients without immunosuppressive drugs revealed lower anti-S in patients with moderate to severe humoral immunodeficiency disease: baseline IgG <3 g/l: 12.0 AU/ml (95%CI 12.0-125.0), baseline IgG 3-5 g/l: 99.9 AU/ml (95%CI 14.4-400.0), baseline IgG >5 g/l: 151.5 AU/ml (95%CI 109.0-400.0), healthy controls 250.0 AU/ml (95%CI 209.0-358.0), p = 0.007.
In most patients with mild to moderate humoral immunodeficiency we found only slightly lower anti-S antibodies compared with healthy controls after two vaccine doses with BNT162b2 and mRNA-1273. However, in patients with a decreased baseline IgG below 3 g/l and/or under immunosuppressive drugs, we found severely impaired humoral immune responses.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0268780</identifier><identifier>PMID: 35679232</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Analysis ; Antibodies ; Antibodies, Viral ; Antibody response ; Biology and Life Sciences ; BNT162 Vaccine ; Common variable immunodeficiency ; Coronaviruses ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Cross-Sectional Studies ; Disease control ; Disease susceptibility ; Drug dosages ; Drugs ; Evaluation ; Humans ; Hypogammaglobulinemia ; Immune response ; Immune response (humoral) ; Immune system ; Immunity, Humoral ; Immunodeficiency ; Immunoglobulin G ; Immunoglobulins ; Immunosuppressive agents ; Influenza ; Medicine and Health Sciences ; Messenger RNA ; mRNA ; mRNA Vaccines ; Patients ; Proteins ; SARS-CoV-2 ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Spike protein ; Statistical analysis ; Subgroups ; Vaccination ; Vaccines ; Vaccines, Synthetic</subject><ispartof>PloS one, 2022-06, Vol.17 (6), p.e0268780-e0268780</ispartof><rights>COPYRIGHT 2022 Public Library of Science</rights><rights>2022 Bitzenhofer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Bitzenhofer et al 2022 Bitzenhofer et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-2e8dfca4907f57b2c4a5f4ccc1ee208e461221cc65dc74392c1c71df65e65c353</citedby><cites>FETCH-LOGICAL-c692t-2e8dfca4907f57b2c4a5f4ccc1ee208e461221cc65dc74392c1c71df65e65c353</cites><orcidid>0000-0003-1512-4279 ; 0000-0002-7717-651X ; 0000-0002-5772-6342</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9182562/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9182562/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35679232$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bitzenhofer, Michaela</creatorcontrib><creatorcontrib>Suter-Riniker, Franziska</creatorcontrib><creatorcontrib>Moor, Matthias B</creatorcontrib><creatorcontrib>Sidler, Daniel</creatorcontrib><creatorcontrib>Horn, Michael P</creatorcontrib><creatorcontrib>Gschwend, Anna</creatorcontrib><creatorcontrib>Staehelin, Cornelia</creatorcontrib><creatorcontrib>Rauch, Andri</creatorcontrib><creatorcontrib>Helbling, Arthur</creatorcontrib><creatorcontrib>Jörg, Lukas</creatorcontrib><title>Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Although mRNA-based vaccines against SARS-CoV-2 induce a robust immune response and prevent infections and hospitalizations, there are limited data on the antibody response in individuals with humoral immunodeficiency. The aim of this study was to evaluate the humoral immune response after two vaccine doses with BNT162b2 or mRNA-1273 in patients with humoral immunodeficiency disease.
This cross-sectional study assessed 39 individuals with hypogammaglobulinemia under immunoglobulin replacement therapy. IgG anti-SARS-CoV-2 spike protein antibodies (anti-S) were measured 4 weeks to 4 months after two doses of an mRNA vaccine against SARS-CoV-2. The proportion of patients, who developed a humoral immune response to the spike protein were evaluated and compared to 19 healthy controls.
After vaccination with two vaccine doses, 26/39 patients (66.7%) with humoral immunodeficiency disease and all healthy controls developed anti-S. In subjects with baseline IgG <3 g/l, only 1/5 (20%) showed a humoral immune response. 10 out of 26 with CVID (38.5%) and 7/9 under immunosuppressive drugs (77.8%) developed no immune response (13 subjects with no response) compared to 0/19 in healthy controls. Subgroup analysis in patients without immunosuppressive drugs revealed lower anti-S in patients with moderate to severe humoral immunodeficiency disease: baseline IgG <3 g/l: 12.0 AU/ml (95%CI 12.0-125.0), baseline IgG 3-5 g/l: 99.9 AU/ml (95%CI 14.4-400.0), baseline IgG >5 g/l: 151.5 AU/ml (95%CI 109.0-400.0), healthy controls 250.0 AU/ml (95%CI 209.0-358.0), p = 0.007.
In most patients with mild to moderate humoral immunodeficiency we found only slightly lower anti-S antibodies compared with healthy controls after two vaccine doses with BNT162b2 and mRNA-1273. However, in patients with a decreased baseline IgG below 3 g/l and/or under immunosuppressive drugs, we found severely impaired humoral immune responses.</description><subject>Analysis</subject><subject>Antibodies</subject><subject>Antibodies, Viral</subject><subject>Antibody response</subject><subject>Biology and Life Sciences</subject><subject>BNT162 Vaccine</subject><subject>Common variable immunodeficiency</subject><subject>Coronaviruses</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Cross-Sectional Studies</subject><subject>Disease control</subject><subject>Disease susceptibility</subject><subject>Drug dosages</subject><subject>Drugs</subject><subject>Evaluation</subject><subject>Humans</subject><subject>Hypogammaglobulinemia</subject><subject>Immune response</subject><subject>Immune response (humoral)</subject><subject>Immune system</subject><subject>Immunity, Humoral</subject><subject>Immunodeficiency</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulins</subject><subject>Immunosuppressive agents</subject><subject>Influenza</subject><subject>Medicine and Health Sciences</subject><subject>Messenger RNA</subject><subject>mRNA</subject><subject>mRNA Vaccines</subject><subject>Patients</subject><subject>Proteins</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike protein</subject><subject>Statistical analysis</subject><subject>Subgroups</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, Synthetic</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11v0zAUhiMEYh_wDxBYQkJwkeKv2MkNUlUBqzQxqYXdWq5z0rpK4i52xvbvcWk2NWgXyBe27Oe8x359TpK8IXhCmCSft67vWl1Pdq6FCaYilzl-lpySgtFUUMyeH61PkjPvtxhnLBfiZXLCMiELyuhpUl30jet0jTrwUckDCg41ix9TdKuNsS14pNfatj6g5XSxTGfuOqXItming4U2ePTbhg3aDCq2afrWlVBZE0_NPSqtB-3hVfKi0rWH18N8nvz69vXn7CK9vPo-n00vUyMKGlIKeVkZzQssq0yuqOE6q7gxhgBQnAMXhFJijMhKIzkrqCFGkrISGYjMsIydJ-8OurvaeTVY5FV0R1BRCMEiMT8QpdNbtetso7t75bRVfzdct1a6C9bUoFY0ZqeCUilKrqnQkq9wSVaYlTymw1Hry5CtXzVQmuhHNGEkOj5p7Uat3a0qSE4zQaPAx0Ggczc9-KAa6w3UtW7B9ft7Sy4zxkUR0ff_oE-_bqDWOj7AtpWLec1eVE0lFhmjsthTkyeoOEporIn1VNm4Pwr4NAqITIC7sNa992q-XPw_e3U9Zj8csRvQddh4V_fBxlIcg_wAms5530H1aDLBat8OD26ofTuooR1i2NvjD3oMeqh_9gfVugTf</recordid><startdate>20220609</startdate><enddate>20220609</enddate><creator>Bitzenhofer, Michaela</creator><creator>Suter-Riniker, Franziska</creator><creator>Moor, Matthias B</creator><creator>Sidler, Daniel</creator><creator>Horn, Michael P</creator><creator>Gschwend, Anna</creator><creator>Staehelin, Cornelia</creator><creator>Rauch, Andri</creator><creator>Helbling, Arthur</creator><creator>Jörg, Lukas</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1512-4279</orcidid><orcidid>https://orcid.org/0000-0002-7717-651X</orcidid><orcidid>https://orcid.org/0000-0002-5772-6342</orcidid></search><sort><creationdate>20220609</creationdate><title>Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease</title><author>Bitzenhofer, Michaela ; Suter-Riniker, Franziska ; Moor, Matthias B ; Sidler, Daniel ; Horn, Michael P ; Gschwend, Anna ; Staehelin, Cornelia ; Rauch, Andri ; Helbling, Arthur ; Jörg, Lukas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-2e8dfca4907f57b2c4a5f4ccc1ee208e461221cc65dc74392c1c71df65e65c353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Antibodies</topic><topic>Antibodies, Viral</topic><topic>Antibody response</topic><topic>Biology and Life Sciences</topic><topic>BNT162 Vaccine</topic><topic>Common variable immunodeficiency</topic><topic>Coronaviruses</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Cross-Sectional Studies</topic><topic>Disease control</topic><topic>Disease susceptibility</topic><topic>Drug dosages</topic><topic>Drugs</topic><topic>Evaluation</topic><topic>Humans</topic><topic>Hypogammaglobulinemia</topic><topic>Immune response</topic><topic>Immune response (humoral)</topic><topic>Immune system</topic><topic>Immunity, Humoral</topic><topic>Immunodeficiency</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulins</topic><topic>Immunosuppressive agents</topic><topic>Influenza</topic><topic>Medicine and Health Sciences</topic><topic>Messenger RNA</topic><topic>mRNA</topic><topic>mRNA Vaccines</topic><topic>Patients</topic><topic>Proteins</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike protein</topic><topic>Statistical analysis</topic><topic>Subgroups</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, Synthetic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bitzenhofer, Michaela</creatorcontrib><creatorcontrib>Suter-Riniker, Franziska</creatorcontrib><creatorcontrib>Moor, Matthias B</creatorcontrib><creatorcontrib>Sidler, Daniel</creatorcontrib><creatorcontrib>Horn, Michael P</creatorcontrib><creatorcontrib>Gschwend, Anna</creatorcontrib><creatorcontrib>Staehelin, Cornelia</creatorcontrib><creatorcontrib>Rauch, Andri</creatorcontrib><creatorcontrib>Helbling, Arthur</creatorcontrib><creatorcontrib>Jörg, Lukas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bitzenhofer, Michaela</au><au>Suter-Riniker, Franziska</au><au>Moor, Matthias B</au><au>Sidler, Daniel</au><au>Horn, Michael P</au><au>Gschwend, Anna</au><au>Staehelin, Cornelia</au><au>Rauch, Andri</au><au>Helbling, Arthur</au><au>Jörg, Lukas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2022-06-09</date><risdate>2022</risdate><volume>17</volume><issue>6</issue><spage>e0268780</spage><epage>e0268780</epage><pages>e0268780-e0268780</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Although mRNA-based vaccines against SARS-CoV-2 induce a robust immune response and prevent infections and hospitalizations, there are limited data on the antibody response in individuals with humoral immunodeficiency. The aim of this study was to evaluate the humoral immune response after two vaccine doses with BNT162b2 or mRNA-1273 in patients with humoral immunodeficiency disease.
This cross-sectional study assessed 39 individuals with hypogammaglobulinemia under immunoglobulin replacement therapy. IgG anti-SARS-CoV-2 spike protein antibodies (anti-S) were measured 4 weeks to 4 months after two doses of an mRNA vaccine against SARS-CoV-2. The proportion of patients, who developed a humoral immune response to the spike protein were evaluated and compared to 19 healthy controls.
After vaccination with two vaccine doses, 26/39 patients (66.7%) with humoral immunodeficiency disease and all healthy controls developed anti-S. In subjects with baseline IgG <3 g/l, only 1/5 (20%) showed a humoral immune response. 10 out of 26 with CVID (38.5%) and 7/9 under immunosuppressive drugs (77.8%) developed no immune response (13 subjects with no response) compared to 0/19 in healthy controls. Subgroup analysis in patients without immunosuppressive drugs revealed lower anti-S in patients with moderate to severe humoral immunodeficiency disease: baseline IgG <3 g/l: 12.0 AU/ml (95%CI 12.0-125.0), baseline IgG 3-5 g/l: 99.9 AU/ml (95%CI 14.4-400.0), baseline IgG >5 g/l: 151.5 AU/ml (95%CI 109.0-400.0), healthy controls 250.0 AU/ml (95%CI 209.0-358.0), p = 0.007.
In most patients with mild to moderate humoral immunodeficiency we found only slightly lower anti-S antibodies compared with healthy controls after two vaccine doses with BNT162b2 and mRNA-1273. However, in patients with a decreased baseline IgG below 3 g/l and/or under immunosuppressive drugs, we found severely impaired humoral immune responses.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>35679232</pmid><doi>10.1371/journal.pone.0268780</doi><tpages>e0268780</tpages><orcidid>https://orcid.org/0000-0003-1512-4279</orcidid><orcidid>https://orcid.org/0000-0002-7717-651X</orcidid><orcidid>https://orcid.org/0000-0002-5772-6342</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2022-06, Vol.17 (6), p.e0268780-e0268780 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2686269663 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Analysis Antibodies Antibodies, Viral Antibody response Biology and Life Sciences BNT162 Vaccine Common variable immunodeficiency Coronaviruses COVID-19 - prevention & control COVID-19 Vaccines Cross-Sectional Studies Disease control Disease susceptibility Drug dosages Drugs Evaluation Humans Hypogammaglobulinemia Immune response Immune response (humoral) Immune system Immunity, Humoral Immunodeficiency Immunoglobulin G Immunoglobulins Immunosuppressive agents Influenza Medicine and Health Sciences Messenger RNA mRNA mRNA Vaccines Patients Proteins SARS-CoV-2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Spike protein Statistical analysis Subgroups Vaccination Vaccines Vaccines, Synthetic |
| title | Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T15%3A50%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Humoral%20response%20to%20mRNA%20vaccines%20against%20SARS-CoV-2%20in%20patients%20with%20humoral%20immunodeficiency%20disease&rft.jtitle=PloS%20one&rft.au=Bitzenhofer,%20Michaela&rft.date=2022-06-09&rft.volume=17&rft.issue=6&rft.spage=e0268780&rft.epage=e0268780&rft.pages=e0268780-e0268780&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0268780&rft_dat=%3Cgale_plos_%3EA706532793%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2686269663&rft_id=info:pmid/35679232&rft_galeid=A706532793&rft_doaj_id=oai_doaj_org_article_b2a5f262276d4a26a74b0d1b03d465c0&rfr_iscdi=true |